Guggenheim Maintains Buy on Janux Therapeutics, Lowers Price Target to $55

Benzinga Newsdesk www.benzinga.com Negative 64.1%

Neg 64.1% Neu 0% Pos 0%

Guggenheim analyst Brad Canino maintains Janux Therapeutics (NASDAQ:JANX) with a Buy and lowers the price target from $58 to $55.